With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

The 12th Outsourcing in Clinical Trials UK & Ireland conference will focus on the region’s future as a clinical trials hub.

"Fresh thinking and a strong community are essential to transforming how we bring medicines to patients," says Rik Van Mol, ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

Excluding sales charges, Institutional Class shares of Columbia Overseas Value Fund returned 13.12% for Q1 of 2025. Click ...

Paavo Penttilä, a new Associate Professor in the Department of Physics at the University of Jyväskylä, Finland, aims to produce new insights into the ...

Keynotes from Bayer, Lonza, MSD, Novo Nordisk, Recipharm, and Teva will showcase how connected platforms and AI can streamline the development of new medicines BARCELONA, May 27, 2025 /PRNewswire/ ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

Access remains limited to these effective but expensive drugs, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...